Definitive Healthcare Q2 2026 earnings report shows revenue of $55.2M, down 9%, with improved customer retention and the launch of AI platform Turbo.
Definitive Healthcare Corp. reported Q2 2026 revenue of $55.2 million, down 9% year-over-year and within the guided range. This decline highlights ongoing challenges in the professional services segment despite improvements in customer retention and the successful launch of new AI-driven products.
Key Takeaways
- Revenue for Q2 2026 was $55.2 million, a 9% decrease from the previous year, with subscription revenue also down 9% to $52.8 million.
- Adjusted EBITDA was $14.6 million, reflecting a 26% margin, and adjusted net income was $7.5 million, leading to non-GAAP earnings of 5 cents per share.
- Net dollar retention rate improved for the second consecutive quarter, indicating stronger customer loyalty and win-backs across various segments, including biopharma and diversified markets.
- Turbo, the new AI-powered healthcare intelligence platform, was launched for pilot testing with select customers, aiming for general availability by year-end.
- Guidance for Q3 2026 was tightened, expecting revenue of $54 to $55 million, reflecting an 8% to 10% decline year-over-year.
Revenue Decline Amid Strategic Initiatives
Revenue for Q2 2026 declined 9% year-over-year to $55.2 million, driven primarily by a 9% decrease in subscription revenues to $52.8 million. Professional services revenues underperformed expectations, resulting in pressure on overall financial performance. Despite these challenges, management noted improvements in customer retention, with a significant uptick in the net dollar retention rate.
| Metric | Q2 2026 | YoY | QoQ |
|---|---|---|---|
| Revenue | $55.2M | -9% | - |
| Adjusted EBITDA | $14.6M | - | - |
| Adjusted Net Income | $7.5M | - | - |
| Free Cash Flow | $11.6M | - | - |
Management highlighted that the decline was partially offset by a strong performance in digital activation, which has gained traction across customer segments. The company continues to focus on maintaining high margins, with an adjusted gross profit of $44.2 million, resulting in an adjusted gross margin of 80% despite a year-over-year contraction due to previous one-time credits.
Improved Customer Retention and Win-Backs
Definitive Healthcare has successfully executed several win-back strategies, particularly in the biopharma and diversified segments. Four significant customers returned after previously leaving for lower-cost competitors. These win-backs affirm the company's belief that quality data and superior service outweigh price considerations in the long run.
“Even customers who believed that an alternative would be just good enough come to recognize that the cost of an inferior data set outweighs the savings,” said Kevin McCarthy, CEO.
Launch of Turbo: A New AI Platform
The launch of Turbo, the company's new AI-powered platform, marks a pivotal point for Definitive Healthcare's growth strategy. Turbo is designed to unify the company's vast healthcare data resources and facilitate autonomous decision-making for clients. The platform is currently in pilot testing with select customers, and feedback from this group will shape the final product prior to its general release.
Management is optimistic about Turbo's potential to enhance customer retention and drive future sales, although they do not expect it to materially impact revenue in 2026.
Guidance Adjustments Reflect Ongoing Market Conditions
For Q3 2026, the company expects revenue between $54 million and $55 million, which represents an 8% to 10% decline year-over-year. This guidance was tightened downward due to weaker bookings in professional services and a shift towards single-year contracts rather than multi-year agreements.
Management has raised their profit guidance midpoint for the full year, expecting adjusted EBITDA of $57 million to $59 million, reflecting disciplined expense management.
Frequently Asked Questions
Did Definitive Healthcare Corp. Class A Common Stock beat earnings estimates in Q2 2026?
No, the company reported a non-GAAP earnings per share of 5 cents, which was in line with expectations but did not exceed them.
What are the expectations for the Turbo platform's impact on revenue?
While the Turbo platform is expected to help with customer retention and engagement, management does not anticipate a significant impact on revenue for 2026, aiming instead for a broader rollout in 2027.
How did the professional services segment perform in Q2 2026?
The professional services segment underperformed expectations, leading to a decline in overall revenue. Management indicated that lighter bookings would also affect Q3 outlook.
What is the forecast for adjusted EBITDA for the full year 2026?
The company expects adjusted EBITDA for the full year to be between $57 million and $59 million, reflecting a commitment to maintaining high margins despite top-line pressures.
In summary, while Definitive Healthcare Corp. faces revenue challenges, improvements in customer retention and strategic investments in AI technologies like Turbo position the company for potential growth as it navigates a shifting market landscape.
This analysis is based on public earnings call materials and is not investment advice.
